Hikma Pharmaceuticals

Hikma Pharmaceuticals signed an agreement with Vectura Group for the global development and commercialization of generic versions of GSK's Ellipta portfolio, using Vectura's Open-Inhale-Close dry powder inhaler device. Hikma made an upfront payment of $15 million.

West-Ward Pharmaceuticals, a subsidiary of Hikma Pharmaceuticals, announced an expansion at its solid-dosage facility in Columbus, Ohio, adding new machinery, equipment, facility improvements, and 65 jobs over 2017.

Hikma Pharmaceuticals signed an exclusive licensing and distribution agreement with Orion Corporation to register, distribute, market and sell Orion's Easyhaler inhaler (budesonide/formoterol) for asthma and COPD in all of Hikma's MENA markets.